{"id":"halobetasol-topical-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypertrichosis"},{"rate":null,"effect":"Acneiform eruptions"},{"rate":null,"effect":"Hypopigmentation"},{"rate":null,"effect":"Perioral dermatitis"}]},"_chembl":{"chemblId":"CHEMBL1200908","moleculeType":"Small molecule","molecularWeight":"484.97"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Halobetasol is a Class I (super-potent) topical corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of cutaneous inflammation. The foam formulation provides enhanced penetration and coverage for inflammatory skin conditions.","oneSentence":"Halobetasol propionate is a potent corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:22.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses"},{"name":"Psoriasis"},{"name":"Eczema"},{"name":"Lichen planus"},{"name":"Other corticosteroid-responsive skin conditions"}]},"trialDetails":[{"nctId":"NCT03992261","phase":"PHASE4","title":"Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis","status":"COMPLETED","sponsor":"Mayne Pharma International Pty Ltd","startDate":"2019-06-14","conditions":"Plaque Psoriasis","enrollment":24},{"nctId":"NCT04571151","phase":"PHASE4","title":"Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis","status":"UNKNOWN","sponsor":"Skin Sciences, PLLC","startDate":"2021-01","conditions":"Plaque Psoriasis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HBP Foam"],"phase":"marketed","status":"active","brandName":"Halobetasol Topical Foam","genericName":"Halobetasol Topical Foam","companyName":"Mayne Pharma International Pty Ltd","companyId":"mayne-pharma-international-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Halobetasol propionate is a potent corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Psoriasis, Eczema.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}